Vaccinoma Hopes To Raise $17M from IPO
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics on April 28, 2006
In Australia, Vaccinoma will be offering 17 million shares a $1.00 each in an initial public offering (IPO) starting on May 4, 2006. The funds will be used to produce and prepare a melanoma cancer vaccine for Phase 3 clinical trials. Previous studies in the US show that the vaccine, which has been almost 15 years in the making, is safe and effective in extending the lifespan of late-stage cancer patients.
"This drug has been "de-risked", so to speak, because it has been under development for over ten years and had no safety issues in over 600 people.
So investors can get into a cycle of development that is near its end and that will appeal to them.
It means they can invest in a company that has a drug that could be very important to Australia, which is potentially not very far from getting approved."
In addition to the melanoma cancer vaccine, part of the funds will also be used to push the company's breast cancer vaccine into Phase 1 human trials.
Read the full report from The Age: Vaccinoma wants $17 million from IPO.

So investors can get into a cycle of development that is near its end and that will appeal to them.
It means they can invest in a company that has a drug that could be very important to Australia, which is potentially not very far from getting approved."
Permalink: Vaccinoma Hopes To Raise $17M from IPO
Tags: IPO stocks biotech raise vaccinoma hopes+raise vaccinoma+hopes stem+cells
Vote for Vaccinoma Hopes To Raise $17M from IPO:
|
Rating: 6.67 out of 3 vote(s) cast.
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
